OncoHost Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to ImmunotherapyWith One Blood Test Pre-Treatment, PROphet® Provides Response Probability for the First Year of Treatment, Plus Analysis of Resistance Associated Pathways for NSCLC Patients BI...